Non-adherence to antipsychotic medication regimens: associations with resource use and costs
- PMID: 15172945
- DOI: 10.1192/bjp.184.6.509
Non-adherence to antipsychotic medication regimens: associations with resource use and costs
Abstract
Background: Several factors are thought to influence resource use and costs in treating schizophrenia.
Aims: To assess the relative impact of non-adherence and other factors associated with resource use and costs incurred by people with schizophrenia.
Method: Secondary analyses were made of data from a 1994 national survey of psychiatric morbidity among adults living in institutions in the UK. Factors potentially relating to resource use and costs were examined using two-part models.
Results: Patients who failed to adhere to their medication regimen were over one-and-a-half times as likely as patients who did adhere to it to report use of in-patient services. Non-adherence is one of the most significant factors in increasing external service costs, by a factor of almost 3. Non-adherence predicted an excess annual cost per patient of approximately 2500 British pounds for in-patient services and over 5000 British pounds for total service use.
Conclusions: Resource use and costs are influenced by various factors. Medication non-adherence consistently exhibits an association with higher costs. Further important factors are patient needs and the ability of the system to address them.
Similar articles
-
Outpatient antipsychotic treatment and inpatient costs of schizophrenia.Schizophr Bull. 2008 Jan;34(1):173-80. doi: 10.1093/schbul/sbm061. Epub 2007 Jun 19. Schizophr Bull. 2008. PMID: 17578893 Free PMC article.
-
Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246. BMC Psychiatry. 2013. PMID: 24094241 Free PMC article.
-
Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.Am J Psychiatry. 2004 Apr;161(4):692-9. doi: 10.1176/appi.ajp.161.4.692. Am J Psychiatry. 2004. PMID: 15056516
-
Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.Curr Med Res Opin. 2007 Oct;23(10):2305-12. doi: 10.1185/030079907X226050. Curr Med Res Opin. 2007. PMID: 17697454 Review.
-
Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).Riv Psichiatr. 2016 Mar-Apr;51(2):47-59. doi: 10.1708/2246.24194. Riv Psichiatr. 2016. PMID: 27183509 Review.
Cited by
-
Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system.Schizophrenia (Heidelb). 2024 Feb 29;10(1):28. doi: 10.1038/s41537-024-00448-2. Schizophrenia (Heidelb). 2024. PMID: 38424086 Free PMC article. Review.
-
Defining and assessing adherence to oral antipsychotics: a review of the literature.Schizophr Bull. 2006 Oct;32(4):724-42. doi: 10.1093/schbul/sbj075. Epub 2006 May 17. Schizophr Bull. 2006. PMID: 16707778 Free PMC article. Review.
-
Risperidone long-acting injection: a review of its long term safety and efficacy.Neuropsychiatr Dis Treat. 2008 Oct;4(5):919-27. doi: 10.2147/ndt.s3311. Neuropsychiatr Dis Treat. 2008. PMID: 19183782 Free PMC article.
-
Costs of treating patients with schizophrenia who have illness-related crisis events.BMC Psychiatry. 2008 Aug 26;8:72. doi: 10.1186/1471-244X-8-72. BMC Psychiatry. 2008. PMID: 18727831 Free PMC article.
-
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.Clin Drug Investig. 2021 Jan;41(1):99-113. doi: 10.1007/s40261-020-00990-8. Epub 2020 Dec 17. Clin Drug Investig. 2021. PMID: 33331979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical